AbbVie develops and sells prescription medicines for immunology, neuroscience and oncology, including Skyrizi and Rinvoq. It last closed at $286.20 on Nov 20, up 0.94% on the day. The next earnings report for ABBV is expected around Wed, Jan 6, 2027, after the close. For the quarter ended Sep 2026, ABBV reported EPS of $2.37 on revenue of $17.40B, with revenue up 10.3% from a year ago. Over its last 8 reports the stock moved an average of 1.9% the session after earnings. Over the last 12 months ABBV insiders bought $0 of stock on the open market and sold $30.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is ABBV in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ABBV.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ABBVStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ABBV · as of the Nov 20 close · updated each morning
Moving sideways
The stock sits between its 20 and 50 day averages. It is 15% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $283.96, and the nearest resistance the Pivot at $287.09.
Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 2.3%/day
Key levels
$302.9352 week high+5.8%
$291.40Swing high (Oct 15)+1.8%
$290.4420 day average+1.5%
$289.34Pivot R1+1.1%
$287.09Pivot+0.3%
$286.20Last close
$283.96Pivot S1−0.8%
$281.23Swing low (Oct 28)−1.7%
$279.0050 day average−2.5%
$266.75100 day average−6.8%
$242.45200 day average−15.3%
$190.7552 week low−33.4%
Indicators
RSI (14)
49.19
Middle of its range
Neutral
MACD
2.48
Below its signal line
Bearish
Stochastic
22.0
Middle of its range
Neutral
ADX (14)
25.1
Trending up
Williams %R
-72.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-68.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.8%
Change over 10 sessions
Bearish
ATR (14)
$6.70
Typical daily range, 2.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 5.2%/day
Key levels
$302.9352 week high+5.8%
$291.40Swing high (Oct 15)+1.8%
$290.4420 day average+1.5%
$289.34Pivot R1+1.1%
$287.09Pivot+0.3%
$286.20Last close
$283.96Pivot S1−0.8%
$281.23Swing low (Oct 28)−1.7%
$279.0050 day average−2.5%
$266.75100 day average−6.8%
$242.45200 day average−15.3%
$190.7552 week low−33.4%
Indicators
RSI (14)
64.57
Strong, overbought above 70
Neutral
MACD
15.70
Above its signal line
Bullish
Stochastic
79.3
Middle of its range
Neutral
ADX (14)
34.8
Trending up
Williams %R
-29.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
106.6
Oversold below −100, overbought above 100
Overbought
Rate of change
+11.3%
Change over 10 sessions
Bullish
ATR (14)
$14.86
Typical daily range, 5.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ABBV
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ABBV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ABBV usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ABBVHow many large options trades hit ABBV, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ABBV in the last 90 days.
From SEC Form 4 filings by ABBV's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.
From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABBV is in one of them and how their past ABBV trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About AbbVie
AbbVie is a biopharmaceutical company based in North Chicago, Illinois. It researches, develops, manufactures and sells prescription medicines in immunology, neuroscience and oncology, including Skyrizi, Rinvoq and Botox Therapeutic. Its treatments are used by patients with autoimmune diseases, migraine, Parkinson's disease and several blood cancers. The company sells its products in many countries around the world.